{
  "Q0": "BRCA1/BRCA2 comprehensive genetic testing",
  "Q1": "Yes",
  "Q2": "Not specified",
  "Q3": "Yes",
  "Q4": "Yes",
  "Q4-Does the patient's clinical presentation match the criteria in those guidelines?": "Yes",
  "Q4-Which guideline(s) apply?": "NCCN",
  "Q5": "Not required",
  "Q6": "No",
  "Q7": "Yes",
  "Q8": "No",
  "Q9": "Yes",
  "Q9-Does this patient have a relevant family history or consanguinity that aligns with the policy?": "Yes",
  "Q10": "No",
  "Q10-If 'No'": "Risk Assessment",
  "Q11": "Yes",
  "Q12": "Yes",
  "Q13": "Not specified",
  "Q14": "Yes",
  "Q14-Please specify the CPT code": "81162",
  "Q15": "Yes",
  "Q15-If 'Yes'": "Patient has Ashkenazi Jewish ancestry which is specifically mentioned in the policy as a qualifying criterion",
  "Q16": "Yes",
  "Q17": "The policy requires that genetic testing be performed in a setting with suitably trained healthcare providers who can provide appropriate pre- and post-test counseling, and that has access to a CLIA-licensed laboratory offering comprehensive variant analysis. The patient should receive genetic counseling before testing. The claim should be submitted with the appropriate CPT code (81162 for comprehensive BRCA1/BRCA2 testing) and the relevant ICD-10 diagnosis codes for breast cancer and Ashkenazi Jewish ancestry.",
  "match": true
}